-
1
-
-
0032954005
-
Comprehensive evaluation of 35 patients with lymphangioleiomyomatosis
-
Chu SC, Horiba K, Usuki J, et al. Comprehensive evaluation of 35 patients with lymphangioleiomyomatosis. Chest 1999; 115: 1041-1052.
-
(1999)
Chest
, vol.115
, pp. 1041-1052
-
-
Chu, S.C.1
Horiba, K.2
Usuki, J.3
-
2
-
-
0032798054
-
Decline in lung function in lymphangioleiomyomatosis: Relation to menopause and progesterone treatment
-
Johnson SR, Tattersfield AE. Decline in lung function in lymphangioleiomyomatosis: relation to menopause and progesterone treatment. Am J Respir Crit Care Med 1999; 160: 628-633.
-
(1999)
Am J Respir Crit Care Med
, vol.160
, pp. 628-633
-
-
Johnson, S.R.1
Tattersfield, A.E.2
-
3
-
-
0032822920
-
Pulmonary lymphangioleiomyomatosis. A study of 69 patients. Groupe d'Etudes et de recherche sur les maladies "Orphelines" pulmonaires (GERM"O"P)
-
Urban T, Lazor R, Lacronique J, et al. Pulmonary lymphangioleiomyomatosis. A study of 69 patients. Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P). Medicine (Baltimore) 1999; 78: 321-337.
-
(1999)
Medicine (Baltimore)
, vol.78
, pp. 321-337
-
-
Urban, T.1
Lazor, R.2
Lacronique, J.3
-
4
-
-
0033671345
-
Clinical experience of lymphangioleiomyomatosis in the UK
-
Johnson SR, Tattersfield AE. Clinical experience of lymphangioleiomyomatosis in the UK. Thorax 2000; 55: 1052-1057.
-
(2000)
Thorax
, vol.55
, pp. 1052-1057
-
-
Johnson, S.R.1
Tattersfield, A.E.2
-
5
-
-
10444277302
-
Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone
-
Taveira-DaSilva AM, Stylianou MP, Hedin CJ, et al. Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest 2004; 126: 1867-1874.
-
(2004)
Chest
, vol.126
, pp. 1867-1874
-
-
Taveira-DaSilva, A.M.1
Stylianou, M.P.2
Hedin, C.J.3
-
6
-
-
30344457333
-
The NHLBI lymphangioleiomyomatosis registry: Characteristics of 230 patients at enrollment
-
Ryu JH, Moss J, Beck GJ, et al. The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med 2006; 173: 105-111.
-
(2006)
Am J Respir Crit Care Med
, vol.173
, pp. 105-111
-
-
Ryu, J.H.1
Moss, J.2
Beck, G.J.3
-
7
-
-
0034082444
-
High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex
-
Costello LC, Hartman TE, Ryu JH. High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex. Mayo Clin Proc 2000; 75: 591-594.
-
(2000)
Mayo Clin Proc
, vol.75
, pp. 591-594
-
-
Costello, L.C.1
Hartman, T.E.2
Ryu, J.H.3
-
9
-
-
0025011582
-
Lymphangioleiomyomatosis. Clinical course in 32 patients
-
Taylor JR, Ryu J, Colby TV, et al. Lymphangioleiomyomatosis. Clinical course in 32 patients. N Engl J Med 1990; 323: 1254-1260.
-
(1990)
N Engl J Med
, vol.323
, pp. 1254-1260
-
-
Taylor, J.R.1
Ryu, J.2
Colby, T.V.3
-
10
-
-
34447261147
-
Pulmonary lymphangioleiomyomatosis in a karyotypically normal man without tuberous sclerosis complex
-
Schiavina M, Di Scioscio V, Contini P, et al. Pulmonary lymphangioleiomyomatosis in a karyotypically normal man without tuberous sclerosis complex. Am J Respir Crit Care Med 2007; 176: 96-98.
-
(2007)
Am J Respir Crit Care Med
, vol.176
, pp. 96-98
-
-
Schiavina, M.1
Di Scioscio, V.2
Contini, P.3
-
11
-
-
0034705207
-
Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis
-
Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA 2000; 97: 6085-6090.
-
(2000)
Proc Natl Acad Sci USA
, vol.97
, pp. 6085-6090
-
-
Carsillo, T.1
Astrinidis, A.2
Henske, E.P.3
-
13
-
-
77953005726
-
Lymphangioleiomyomatosis (LAM): Molecular insights lead to targeted therapies
-
Glasgow CG, Steagall WK, Taveira-Dasilva A, et al. Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies. Respir Med 2010; 104: Suppl. 1, S45-S58.
-
(2010)
Respir Med
, vol.104
, pp. S45-S58
-
-
Glasgow, C.G.1
Steagall, W.K.2
Taveira-Dasilva, A.3
-
14
-
-
65949104047
-
Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement
-
Glasgow CG, Avila NA, Lin JP, et al. Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement. Chest 2009; 135: 1293-1300.
-
(2009)
Chest
, vol.135
, pp. 1293-1300
-
-
Glasgow, C.G.1
Avila, N.A.2
Lin, J.P.3
-
15
-
-
33846073861
-
Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis
-
Seyama K, Kumasaka T, Souma S, et al. Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. Lymphat Res Biol 2006; 4: 143-152.
-
(2006)
Lymphat Res Biol
, vol.4
, pp. 143-152
-
-
Seyama, K.1
Kumasaka, T.2
Souma, S.3
-
16
-
-
77956799312
-
Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases
-
Young LR, Vandyke R, Gulleman PM, et al. Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest 2010; 138: 674-681.
-
(2010)
Chest
, vol.138
, pp. 674-681
-
-
Young, L.R.1
Vandyke, R.2
Gulleman, P.M.3
-
17
-
-
84881343915
-
Serum VEGF-D concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: A prospective analysis of the multicenter international lymphangioleiomyomatosis efficacy of sirolimus (MILES) trial
-
Young LR, Lee HS, Inoue Y, et al. Serum VEGF-D concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. Lancet Respir Med 2013; 1: 445-452.
-
(2013)
Lancet Respir Med
, vol.1
, pp. 445-452
-
-
Young, L.R.1
Lee, H.S.2
Inoue, Y.3
-
19
-
-
39449100827
-
Lymphangioleiomyomatosis: A clinical update
-
McCormack FX. Lymphangioleiomyomatosis: a clinical update. Chest 2008; 133: 507-516.
-
(2008)
Chest
, vol.133
, pp. 507-516
-
-
McCormack, F.X.1
-
20
-
-
4544315390
-
Survival and disease progression in UK patients with lymphangioleiomyomatosis
-
Johnson SR, Whale CI, Hubbard RB, et al. Survival and disease progression in UK patients with lymphangioleiomyomatosis. Thorax 2004; 59: 800-803.
-
(2004)
Thorax
, vol.59
, pp. 800-803
-
-
Johnson, S.R.1
Whale, C.I.2
Hubbard, R.B.3
-
21
-
-
2542551101
-
Low initial KCO predicts rapid FEV1 decline in pulmonary lymphangioleiomyomatosis
-
Lazor R, Valeyre D, Lacronique J, et al. Low initial KCO predicts rapid FEV1 decline in pulmonary lymphangioleiomyomatosis. Respir Med 2004; 98: 536-541.
-
(2004)
Respir Med
, vol.98
, pp. 536-541
-
-
Lazor, R.1
Valeyre, D.2
Lacronique, J.3
-
22
-
-
12144249965
-
Decline in lung function in the busselton health study: The effects of asthma and cigarette smoking
-
James AL, Palmer LJ, Kicic E, et al. Decline in lung function in the Busselton Health Study: the effects of asthma and cigarette smoking. Am J Respir Crit Care Med 2005; 171: 109-114.
-
(2005)
Am J Respir Crit Care Med
, vol.171
, pp. 109-114
-
-
James, A.L.1
Palmer, L.J.2
Kicic, E.3
-
23
-
-
84895437651
-
A 2-year randomised placebo-controlled trial of doxycycline for lymphangioleiomyomatosis
-
Chang WY, Cane JL, Kumaran M, et al. A 2-year randomised placebo-controlled trial of doxycycline for lymphangioleiomyomatosis. Eur Respir J 2014; 43: 1114-1123.
-
(2014)
Eur Respir J
, vol.43
, pp. 1114-1123
-
-
Chang, W.Y.1
Cane, J.L.2
Kumaran, M.3
-
24
-
-
39449120136
-
Effect of a gonadotrophin-releasing hormone analogue on lung function in lymphangioleiomyomatosis
-
Harari S, Cassandro R, Chiodini I, et al. Effect of a gonadotrophin-releasing hormone analogue on lung function in lymphangioleiomyomatosis. Chest 2008; 133: 448-454.
-
(2008)
Chest
, vol.133
, pp. 448-454
-
-
Harari, S.1
Cassandro, R.2
Chiodini, I.3
-
25
-
-
79955510505
-
Efficacy and safety of sirolimus in lymphangioleiomyomatosis
-
McCormack FX, Inoue Y, Moss J, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011; 364: 1595-1606.
-
(2011)
N Engl J Med
, vol.364
, pp. 1595-1606
-
-
McCormack, F.X.1
Inoue, Y.2
Moss, J.3
-
26
-
-
38049169559
-
Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis
-
Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008; 358: 140-151.
-
(2008)
N Engl J Med
, vol.358
, pp. 140-151
-
-
Bissler, J.J.1
McCormack, F.X.2
Young, L.R.3
-
27
-
-
38049177875
-
Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis
-
Davies DM, Johnson SR, Tattersfield AE, et al. Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N Engl J Med 2008; 358: 200-203.
-
(2008)
N Engl J Med
, vol.358
, pp. 200-203
-
-
Davies, D.M.1
Johnson, S.R.2
Tattersfield, A.E.3
-
28
-
-
84874746597
-
Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): A multicentre, randomised, double-blind, placebo-controlled trial
-
Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013; 381: 817-824.
-
(2013)
Lancet
, vol.381
, pp. 817-824
-
-
Bissler, J.J.1
Kingswood, J.C.2
Radzikowska, E.3
-
30
-
-
20144382361
-
Minimal clinically important differences in COPD lung function
-
Donohue JF. Minimal clinically important differences in COPD lung function. COPD 2005; 2: 111-124.
-
(2005)
COPD
, vol.2
, pp. 111-124
-
-
Donohue, J.F.1
-
31
-
-
43249086546
-
Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors
-
O'Donnell A, Faivre S, Burris HAIII, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008; 26: 1588-1595.
-
(2008)
J Clin Oncol
, vol.26
, pp. 1588-1595
-
-
O'Donnell, A.1
Faivre, S.2
Burris, H.A.3
-
32
-
-
84897056068
-
Adverse event management in patients with advanced cancer receiving oral everolimus: Focus on breast cancer
-
Aapro M, Andre F, Blackwell K, et al. Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer. Ann Nutr Metab 2014; 25: 763-773.
-
(2014)
Ann Nutr Metab
, vol.25
, pp. 763-773
-
-
Aapro, M.1
Andre, F.2
Blackwell, K.3
-
33
-
-
84919906810
-
A randomized phase II study of everolimus for advanced pancreatic neuroendocrine tumors in Chinese patients
-
Yao J, Wang JY, Liu Y, et al. A randomized phase II study of everolimus for advanced pancreatic neuroendocrine tumors in Chinese patients. Med Oncol 2014; 31: 251-256.
-
(2014)
Med Oncol
, vol.31
, pp. 251-256
-
-
Yao, J.1
Wang, J.Y.2
Liu, Y.3
-
34
-
-
84889008307
-
Safety and efficacy of everolimus with exemestane vs exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2
-
Pritchard KI, Burris HAIII, Ito Y, et al. Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. Clin Breast Cancer 2013; 13: 421-432.
-
(2013)
Clin Breast Cancer
, vol.13
, pp. 421-432
-
-
Pritchard, K.I.1
Burris, H.A.2
Ito, Y.3
-
35
-
-
77956227464
-
Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors
-
Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010; 116: 4256-4265.
-
(2010)
Cancer
, vol.116
, pp. 4256-4265
-
-
Motzer, R.J.1
Escudier, B.2
Oudard, S.3
-
36
-
-
78049510428
-
Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis
-
Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010; 363: 1801-1811.
-
(2010)
N Engl J Med
, vol.363
, pp. 1801-1811
-
-
Krueger, D.A.1
Care, M.M.2
Holland, K.3
-
37
-
-
84873653141
-
Everolimus long-term safety and efficacy in subependymal giant-cell astrocytoma
-
Krueger DA, Care MM, Agricola K, et al. Everolimus long-term safety and efficacy in subependymal giant-cell astrocytoma. Neurology 2013; 80: 574-580.
-
(2013)
Neurology
, vol.80
, pp. 574-580
-
-
Krueger, D.A.1
Care, M.M.2
Agricola, K.3
-
38
-
-
84872088946
-
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): A multicentre, randomised, placebo-controlled phase 3 trial
-
Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013; 381: 125-132.
-
(2013)
Lancet
, vol.381
, pp. 125-132
-
-
Franz, D.N.1
Belousova, E.2
Sparagana, S.3
-
39
-
-
84925231101
-
Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study
-
Franz DN, Belousova E, Sparagana S, et al. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. Lancet Oncol 2014; 15: 1513-1520.
-
(2014)
Lancet Oncol
, vol.15
, pp. 1513-1520
-
-
Franz, D.N.1
Belousova, E.2
Sparagana, S.3
-
40
-
-
79959639375
-
Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus
-
Taveira-DaSilva AM, Hathaway O, Stylianou M, et al. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus. Ann Intern Med 2011; 154: 797-805.
-
(2011)
Ann Intern Med
, vol.154
, pp. 797-805
-
-
Taveira-DaSilva, A.M.1
Hathaway, O.2
Stylianou, M.3
-
41
-
-
84916226614
-
Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis
-
Yao J, Taveira-DaSilva AM, Jones AM, et al. Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis. Am J Respir Crit Care Med 2014; 190: 1273-1282.
-
(2014)
Am J Respir Crit Care Med
, vol.190
, pp. 1273-1282
-
-
Yao, J.1
Taveira-DaSilva, A.M.2
Jones, A.M.3
-
42
-
-
84882833554
-
The efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis
-
Ando K, Kurihara M, Kataoka H, et al. The efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis. Respir Invest 2013; 51: 175-183.
-
(2013)
Respir Invest
, vol.51
, pp. 175-183
-
-
Ando, K.1
Kurihara, M.2
Kataoka, H.3
-
43
-
-
79959262531
-
Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: A phase 2 trial
-
Davies DM, de Vries PJ, Johnson SR, et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res 2011; 17: 4071-4081.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 4071-4081
-
-
Davies, D.M.1
De Vries, P.J.2
Johnson, S.R.3
-
45
-
-
17144373720
-
Inhibitors of the mammalian target of rapamycin
-
Dancey JE. Inhibitors of the mammalian target of rapamycin. Exp Opin Invest Drugs 2005; 14: 313-328.
-
(2005)
Exp Opin Invest Drugs
, vol.14
, pp. 313-328
-
-
Dancey, J.E.1
-
46
-
-
84919360810
-
Chronic sirolimus therapy for lymphangioleiomyomatosis
-
McCormack FX. Chronic sirolimus therapy for lymphangioleiomyomatosis. Am J Respir Crit Care Med 2014; 190: 1332-1333.
-
(2014)
Am J Respir Crit Care Med
, vol.190
, pp. 1332-1333
-
-
McCormack, F.X.1
|